Vyriad to Build State-of-the-Art Facility for Manufacturing Oncolytic Virus Anti-Cancer Vaccines in Rochester, Minn.
Vyriad and Sanford Health launch Phase I clinical trial to use VSV to fight cancer.
Tessa Therapeutics and Vyriad Form Partnership to Create
Next Generation of Cancer Immunotherapy Treatments
Vyriad Appoints Alvin E. McQuinn to Board of Directors
Vyriad Announces Agreement With Imanis Life Sciences for Development of Theranostic Tests to Predict Responsiveness to Oncolytic Virotherapy
Vyriad Signs Exclusive License Agreement for STING Technology for Development of Enhanced Oncolytic Virotherapy Treatments
Vyriad Appoints Alice Bexon, MD, as Chief Medical Officer
Profectus and Vyriad Form Global Collaboration to Develop Oncolytic Recombinant VSV (rVSV) Vaccines for Cancer Immunotherapy
Omnis Pharma and Magnis Therapeutics Merge to Form Vyriad, a Clinical-Stage Oncolytic Immunovirotherapy Development Company
Medimmune Enters Licensing Agreement with Omnis Pharmaceuticals* for Oncolytic Viruses Immuno-oncology